Why We Need to Rethink Ethnicity-Based Genetic Testing
By Shivani Nazareth,
US News & World Report
| 11. 07. 2016
A recent study noted racial bias in the genetic databases that are important to furthering research in precision medicine. The data is skewed toward a European Caucasian population, which makes it difficult to interpret genetic variants in minority groups. As the U.S. population increasingly diversifies, we need to challenge ourselves to do better. A good place to begin is pregnancy, when nearly every woman in the U.S. is offered genetic carrier screening.
Carrier screening is the practice of testing of both mom and dad for inherited conditions that may be passed along to their baby. A pregnant woman is typically offered screening – for one condition, a few conditions or a panel – based upon her self-reported ethnic category. As an example, black patients are offered screening for sickle cell disease, Southeast Asian patients for thalassemias and Ashkenazi Jewish patients for a panel that includes Canavan and Tay-Sachs disease, among others. This approach is based on a public health model that factors cost and the availability of a reliable test into the screening equation. In the past few...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...